Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract characterized by diarrhea, abdominal pain, and weight loss. The primary goal of CD treatment is to induce and maintain remission. The treatment of adult CD typically begins with safe, albeit less-efficacious, conventional agents (e.g., 5-ASAs) but often progresses to more-potent drugs, such as immunosuppressants and/or biologics. However, this scenario is changing, and more physicians are prescribing biologics as first-line therapy for recently diagnosed CD. Among the biologics, tumor necrosis factor (TNF)-alpha inhibitors (e.g., J&J Innovative Medicine’s Remicade, AbbVie’s Humira) have a relatively constant patient share; however, non-TNF biologics (e.g., Takeda’s Entyvio, J&J Innovative Medicine’s Stelara) have experienced a sharp increase in patient share. Nonetheless, later-to-market oral targeted therapies, such as the Janus-activated kinase (JAK) inhibitor Rinvoq (AbbVie), are increasing the market competition among later-line targeted therapies. The entry of adalimumab biosimilars in the United States has further impacted the market dynamics. This content provides manufacturers of current CD treatments and developers of novel CD agents with insights into the use of these drugs and into the market trends in the CD space.
Markets covered: United States
Key companies: Janssen, AbbVie, Takeda, UCB
Key drugs: Humira, Remicade, Entyvio, Stelara, Cimzia, biosimilar infliximab, aminosalicylates, immunosuppressants
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Key feature
Dashboard featuring interactive visuals, easy navigation, and expanded analyses